Caplin Point Laboratories has informed that it enclosed Press Release regarding grant of USFDA approval for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection to its Subsidiary Caplin Steriles.
The above information is a part of company’s filings submitted to BSE.